
Stephen E. Jones
Examiner (ID: 2262, Phone: (571)272-1762 , Office: P/2842 )
| Most Active Art Unit | 2817 |
| Art Unit(s) | 2843, 2842, 2817 |
| Total Applications | 2057 |
| Issued Applications | 1739 |
| Pending Applications | 89 |
| Abandoned Applications | 263 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17828294
[patent_doc_number] => 20220265598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => EXTREME LOW DOSE THC AS A THERAPEUTIC AND PROPHYLACTIC AGENT FOR ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/738351
[patent_app_country] => US
[patent_app_date] => 2020-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17368
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738351
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/738351 | Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease | Jan 8, 2020 | Issued |
Array
(
[id] => 16482325
[patent_doc_number] => 20200375925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => METHODS OF TREATING MUSCLE CRAMPING AND RELATED COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 16/727508
[patent_app_country] => US
[patent_app_date] => 2019-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16727508
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/727508 | METHODS OF TREATING MUSCLE CRAMPING AND RELATED COMPOSITIONS | Dec 25, 2019 | Abandoned |
Array
(
[id] => 17413974
[patent_doc_number] => 20220048878
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/297752
[patent_app_country] => US
[patent_app_date] => 2019-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4887
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297752
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/297752 | IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS | Dec 11, 2019 | Pending |
Array
(
[id] => 16238178
[patent_doc_number] => 20200255412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => Imidazolecarboxamides and Their Use as FAAH Inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/705277
[patent_app_country] => US
[patent_app_date] => 2019-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6225
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705277
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/705277 | Imidazolecarboxamides and Their Use as FAAH Inhibitors | Dec 5, 2019 | Abandoned |
Array
(
[id] => 17355324
[patent_doc_number] => 20220016120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS
[patent_app_type] => utility
[patent_app_number] => 17/311633
[patent_app_country] => US
[patent_app_date] => 2019-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3860
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311633
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/311633 | METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS | Dec 4, 2019 | Pending |
Array
(
[id] => 17385560
[patent_doc_number] => 20220033412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE
[patent_app_type] => utility
[patent_app_number] => 17/299236
[patent_app_country] => US
[patent_app_date] => 2019-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299236
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/299236 | 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage | Dec 3, 2019 | Issued |
Array
(
[id] => 16009067
[patent_doc_number] => 20200179376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE
[patent_app_type] => utility
[patent_app_number] => 16/702939
[patent_app_country] => US
[patent_app_date] => 2019-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22548
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 294
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16702939
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/702939 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | Dec 3, 2019 | Abandoned |
Array
(
[id] => 17368241
[patent_doc_number] => 20220023293
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => EZH2- FGFR INHIBITION IN CANCER
[patent_app_type] => utility
[patent_app_number] => 17/297038
[patent_app_country] => US
[patent_app_date] => 2019-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297038
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/297038 | EZH2- FGFR INHIBITION IN CANCER | Dec 2, 2019 | Abandoned |
Array
(
[id] => 17655471
[patent_doc_number] => 20220175936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/309435
[patent_app_country] => US
[patent_app_date] => 2019-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13412
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309435
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/309435 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Nov 26, 2019 | Pending |
Array
(
[id] => 18195594
[patent_doc_number] => 20230049113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2
[patent_app_type] => utility
[patent_app_number] => 17/294959
[patent_app_country] => US
[patent_app_date] => 2019-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37783
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294959
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/294959 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Nov 25, 2019 | Abandoned |
Array
(
[id] => 15930885
[patent_doc_number] => 20200157076
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => ACLY INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/684644
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33292
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 373
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684644
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684644 | ACLY inhibitors and uses thereof | Nov 14, 2019 | Issued |
Array
(
[id] => 16156427
[patent_doc_number] => 20200216446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
[patent_app_type] => utility
[patent_app_number] => 16/685841
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30808
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685841
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685841 | Synthesis of key intermediate of KRAS G12C inhibitor compound | Nov 14, 2019 | Issued |
Array
(
[id] => 15927889
[patent_doc_number] => 20200155578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => Pharmaceutical Formulations for Subcutaneous Administration
[patent_app_type] => utility
[patent_app_number] => 16/684874
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17210
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684874
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684874 | Pharmaceutical formulations for subcutaneous administration | Nov 14, 2019 | Issued |
Array
(
[id] => 16837804
[patent_doc_number] => 20210145816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => PHARMACEUTICAL FORMULATION OF LONAFARNIB WITH A SULFOBUTYLETHER BETA-CYCLODEXTRIN
[patent_app_type] => utility
[patent_app_number] => 16/685632
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1042
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685632
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685632 | PHARMACEUTICAL FORMULATION OF LONAFARNIB WITH A SULFOBUTYLETHER BETA-CYCLODEXTRIN | Nov 14, 2019 | Abandoned |
Array
(
[id] => 16824141
[patent_doc_number] => 20210139434
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => ANTICANCER COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND A METHOD OF TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/681086
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 237
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681086
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/681086 | Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer | Nov 11, 2019 | Issued |
Array
(
[id] => 16924022
[patent_doc_number] => 11045478
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-29
[patent_title] => Salts of potassium ATP channel openers and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/680093
[patent_app_country] => US
[patent_app_date] => 2019-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 51
[patent_figures_cnt] => 51
[patent_no_of_words] => 56802
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680093
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/680093 | Salts of potassium ATP channel openers and uses thereof | Nov 10, 2019 | Issued |
Array
(
[id] => 15586155
[patent_doc_number] => 20200069612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-05
[patent_title] => Pharmaceutical Composition Of S-Ketamine Hydrochloride
[patent_app_type] => utility
[patent_app_number] => 16/675780
[patent_app_country] => US
[patent_app_date] => 2019-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -69
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675780
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/675780 | Pharmaceutical Composition Of S-Ketamine Hydrochloride | Nov 5, 2019 | Abandoned |
Array
(
[id] => 15862673
[patent_doc_number] => 20200138740
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA)
[patent_app_type] => utility
[patent_app_number] => 16/675267
[patent_app_country] => US
[patent_app_date] => 2019-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19757
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675267
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/675267 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | Nov 5, 2019 | Issued |
Array
(
[id] => 17290905
[patent_doc_number] => 20210386744
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => SILDENAFIL FOR USE IN THE TREATMENT OF OSTEOARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 17/288609
[patent_app_country] => US
[patent_app_date] => 2019-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288609
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/288609 | SILDENAFIL FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | Oct 24, 2019 | Pending |
Array
(
[id] => 19737163
[patent_doc_number] => 12213970
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/285916
[patent_app_country] => US
[patent_app_date] => 2019-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19144
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 178
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285916
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/285916 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | Oct 23, 2019 | Issued |